ACP6

Across TCGA pan-cancer cohorts, ACP6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACP6 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ACP6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ACP6 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, GBM, and HNSC are the cancer types where ACP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.632	1.000	.004	13	view →
GBM	DFS	Median	All	0.269	0.464	.003	7	view →
HNSC	DFS	Median	II,III,IV	0.901	0.984	.022	7	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →
CCRCC	OS	Tertile	II,III,IV	0.978	0.202	.022	4	view →
LSCC	DFS	Quartile	II,III,IV	0.380	1.000	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACP6–LUAD (OS)

Open the LUAD breakdown →